Research programme: ischaemia reperfusion injury therapeutics - DecImmune Therapeutics

Drug Profile

Research programme: ischaemia reperfusion injury therapeutics - DecImmune Therapeutics

Alternative Names: Anti-N2 monoclonal antibody - DecImmune Therapeutics; Anti-N2F(ab')2 MAb; Antibody 21G6 - DecImmune Therapeutics; DeciMab; N2 inhibitors - DecImmune Therapeutics; Non-muscle myosin heavy-chain II inhibitors - DecImmune Therapeutics; Synthetic N2 peptide - DecImmune Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DecImmune Therapeutics
  • Class Antibodies; Monoclonal antibodies; Peptides
  • Mechanism of Action Inflammation mediator inhibitors; Myosin type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myocardial ischaemia; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Myocardial-ischaemia in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Reperfusion-injury in USA
  • 03 Oct 2014 DecImmune receives SBIR phase IIb grant from the US National Institutes of Health for development of its N2-targeted monoclonal therapeutic in vascular inflammatory diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top